Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability

Treatment with HSV1716 via intralesional administration has proven successful for melanoma patients with the hope that oncolytic virotherapy would become another weapon in the systemic anticancer therapy (SACT) arsenal. In addition to challenges surrounding the systemic delivery of oncolytic viruses...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, Faith, Conner, Joe, Danson, Sarah, Muthana, Munitta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Molecular Biosciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240779/
https://www.ncbi.nlm.nih.gov/pubmed/35782876
http://dx.doi.org/10.3389/fmolb.2022.889395

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9240779/
https://www.ncbi.nlm.nih.gov/pubmed/35782876
http://dx.doi.org/10.3389/fmolb.2022.889395

Ejemplares similares